Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Meningioma Clinical Trial

Official title:

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03936426
• Other study ID #: CL02
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 9, 2018
• Est. completion date: September 19, 2019

Study information

• Verified date: April 2020
• Source: Clarity Pharmaceuticals Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to investigate the safety and tolerability of a single dose of Cu-64 SARTATE and multiple doses of Cu-67 SARTATE administered to participants with meningioma. All participants in this study will be injected with a single dose of Cu-64 SARTATE to demonstrate how it is absorbed in the body. Then participants will receive individualised doses of Cu-67 SARTATE for up to 4 cycles.

Description:

This is a single centre, open label, non-randomised, single cohort, multiple dose study of Cu-67 SARTATE administered to male and female participants diagnosed with grade I, II, or III meningioma. The maximum allowable dose will be calculated using dosimetry data acquired from PET/CT scans completed during a pre-treatment diagnostic & dosimetry phase using Cu-64 SARTATE, a structurally identical molecule radiolabelled with copper-64 (Cu-64), instead of copper-67 (Cu-67). Approximately 6 participants will be enrolled in the study. Participants will have up to 4 therapy cycles (6-12 weeks apart). Safety visits will occur between each cycle at bi-weekly intervals to ensure the participant meets the safety criteria prior to their next therapy. An efficacy assessment will be conducted following cycle 2 to determine if a subsequent 2 cycles of therapy will be administered. Participants who complete all four cycles of Cu-67 SARTATE therapy, will complete their final study visit at 12 weeks post administration of cycle 4.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: September 19, 2019
• Est. primary completion date: September 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent.

2. Age greater than or equal to 50 years.

3. Life expectancy greater than or equal to 3 months.

4. Has adequate organ function as defined by the following laboratory values obtained within 28 days prior to administration of Cu-64 SARTATE:

1. Estimated glomerular filtration rate (eGFR) greater than 40ml/min as measured using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3.0 x upper limit of normal (ULN).

3. QT interval less than /=450msec as measured by 12 lead ECG.

5. Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.

6. Diagnosis of recurrent or progressive histologically confirmed WHO grade I-III meningioma which has failed standard of care therapies. Patients will be considered to have failed standard care when they have disease that is progressing despite standard treatment (primarily radiotherapy) or where, in the opinion of their treating physician, further standard therapy is considered to be of sufficiently high risk of complication as to warrant consideration of alternate therapies.

7. Male participants must agree to use contraception methods from Day 0 through to 4 weeks after the last dose of Cu-67 SARTATE.

8. A female participant is eligible to participate if she is of:

1. Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and oestradiol less than 40 pg/ml (less than 140 pmol/l) is confirmatory].

2. Child-bearing potential and agrees to use contraception methods for an appropriate period of time (as determined by the Investigator) prior to Day 0 to sufficiently minimize the risk of pregnant females being enrolled. These measures are the combination of a barrier method AND established (greater than 2 cycles) hormonal methods (e.g. the oral contraceptive pill). Absolute sexual abstinence may be considered acceptable at the discretion of the investigator. Abstinence for the 12 days prior to therapy to allow for serum B-hCG assessment which should then ensure the patient is not pregnant prior to therapy administration.

3. Female participants must agree to use contraception until four weeks after the last dose of Cu-67 SARTATE.

Exclusion Criteria:

1. Known sensitivity or allergy to somatostatin analogues.

2. Participants who have received interventional treatment for their meningioma within the four weeks prior to Day 0.

3. Any major surgery within the four weeks prior to Day 0.

4. Any additional planned interventions, including surgery or radiation therapy that would interfere with safety or efficacy assessments.

5. Treatment with long acting somatostatin analogues within 28 days prior to Day 0. Treatment with short acting somatostatin analogues within 24 hours prior to Day 0.

6. Any other malignancy in the past 5 years except for cervical intraepithelial neoplasia (CIN) of the cervix, squamous cell carcinoma (SCC) of the skin, basal cell carcinoma (BCC) of the skin or clinical insignificant prostate cancer not requiring prior therapy.

7. Breastfeeding females and pregnant females.

8. Treatment with any investigational agent received within four weeks prior to Day 0.

9. Participants unwilling or unable to comply with protocol requirements.

10. Urinary or faecal incontinence of sufficient degree to be of concern for contamination risk in the opinion of the Investigator.

11. Peptide receptor radionuclide therapy (PRRT) at any time prior to enrolment in the study.

Related Conditions & MeSH terms

• Meningioma

Intervention

Drug:
• Cu-64 SARTATE and Cu-67 SARTATE
Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug

Locations

Country	Name	City	State
Australia	Royal North Shore Hospital	Sydney	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Clarity Pharmaceuticals Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of multiple doses of Cu-67 SARTATE using CTCAE version 4.03	Safety will be assessed via vital signs, laboratory tests, physical examinations, ECGs and spontaneous adverse event reporting.	55 weeks
Primary	Safety and tolerability of a single dose of Cu-64 SARTATE using CTCAE version 4.03	Safety will be assessed via vital signs, laboratory tests, physical examinations, ECGs and spontaneous adverse event reporting.	56 weeks
Secondary	Absorbed dose of Cu-64 SARTATE in target, non-target organs and whole body.	Absorbed doses (mSv/MBq) will be calculated using PET/CT scans acquired at 1, 4 and 24 hours post administration of Cu-64 SARTATE.	1, 4 and 24 hours post administration of Cu-64 SARTATE.
Secondary	Absorbed dose of Cu-67 SARTATE in target, non-target organs and whole body.	Absorbed doses (mSv/MBq) will be calculated using SPECT/CT scans acquired at 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.	1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.
Secondary	Maximum and mean SUV of Cu-64 SARTATE in target organs and SSTR binding lesions.	Maximum and mean SUV will be calculated using PET/CT scans acquired at 1, 4 and 24 hours post administration of Cu-64 SARTATE.	1, 4 and 24 hours post administration of Cu-64 SARTATE.
Secondary	Maximum and mean SUV of Cu-67 SARTATE in target organs and SSTR binding lesions.	Maximum and mean SUV will be calculated using SPECT/CT scans acquired at 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.	1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.
Secondary	Activity of Cu-64 SARTATE in target and non-target organs and SSTR binding lesions as a percentage of the administered dose.	The percentage of the administered dose will be calculated using PET/CT scans acquired at 1, 4 and 24 hours post administration of Cu-64 SARTATE.	1, 4 and 24 hours post administration of Cu-64 SARTATE.
Secondary	Activity of Cu-67 SARTATE in target and non-target organs and SSTR binding lesions as a percentage of the administered dose.	The percentage of the administered dose will be calculated using SPECT/CT scans acquired at 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.	1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.
Secondary	Objective Response	Objective response to therapy will be assessed according to the RANO Response Criteria for Meningioma, as measured by MRI and clinical status.	At 6 weeks post second administration of Cu-67 SARTATE, as well as at 6 and 12 weeks following the fourth administration.
Secondary	Qualitative analysis of PET/CT scans post administration of Cu-64 SARTATE.	Qualitative analysis of PET/CT scans to identify uptake patterns.	1, 4 and 24 hours post administration of Cu-64 SARTATE.
Secondary	Qualitative analysis of SPECT/CT scans post administration of Cu-67 SARTATE.	Qualitative analysis of SPECT/CT scans to identify uptake patterns.	1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.